Report Publication Announcement • Nov 30, 2020
Report Publication Announcement
Open in ViewerOpens in native device viewer
BERGENBIO TO PRESENT UPDATED CLINICAL DATA AT ASH 2020 MEETING
Bergen, Norway, 30 November 2020 - BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical need, is pleased to announce it has been accepted for a
poster presentation at the 62[nd] Annual American Society of Hematology (ASH)
Meeting, being held virtually from 5-8 December 2020.
The poster will provide an update from the Company's Phase II study of
bemcentinib (BGBC003) in combination with low dose cytarabine (LDAC) in elderly
relapsed AML patients, and the Phase II BERGAMO trial in patients with high-risk
MDS or AML.
Abstracts have been announced online, and details of the presentation are below.
Title: The Combination of AXL Inhibitor Bemcentinib and Low Dose Cytarabine Is
Well Tolerated and Efficacious in Elderly Relapsed AML Patients: Update from the
Ongoing BGBC003 phase II Trial (NCT02488408)
Date: Sunday, December 6, 2020
Session name: 613. Acute Myeloid Leukemia: Clinical Studies: Poster II
Time: 7.00am - 3.30pm (Pacific Time) / 4.00pm - 12.30am (7[th] Dec) (CET)
Link online to abstract
here (https://ash.confex.com/ash/2020/webprogram/Paper136566.html)
Title: Efficacy and Safety of Bemcentinib in Patients with Myelodysplastic
Syndromes or Acute Myeloid Leukemia Failing Hypomethylating Agents
Date: Saturday, December 5, 2020
Session name: 637 Myelodysplastic Syndromes - Clinical Studies: Poster I
Hematology Disease Topics & Pathways: Diseases, Therapies, MDS, Myeloid
Malignancies, Clinically relevant
Time: 7.00am - 3.30pm (Pacific Time) / 4.00pm - 12.30am (7[th] Dec) (CET)
Link online to abstract
here (https://ash.confex.com/ash/2020/webprogram/Paper140240.html)
The poster will be available at www.bergenbio.com in the section:
Investors/Presentations at the date of the ASH 2020 meeting.
- End -
About AML and the BGBC003 trial
Acute myeloid leukaemia (AML) is a rapidly progressing blood cancer. AML is the
most common form of acute leukaemia in adults, where malignant AML blasts
interfere with the normal functioning of the bone marrow leading to a multitude
of complications like anaemia, infections and bleeding. AML is diagnosed in over
20,000 patients in the US annually and is rapidly lethal if left untreated.
Successful treatment typically requires intensive therapy or bone marrow
transplantation, and relapse and resistance are common. Consequently, there is
an urgent need for effective novel therapies in relapsed/refractory patients,
particularly those that are ineligible for intensive therapy or bone marrow
transplant.
The BGBC003 trial is a phase Ib/II multi-centre open label study of bemcentinib
in combination with cytarabine (part B2) and decitabine (part B3) in patients
with AML who are unsuitable for intensive chemotherapy as a result of advanced
age or existing comorbidities. Up to 28 patients will be enrolled at centres in
the US, Norway, Germany and Italy.
For more information please access trial NCT02488408 at www.clinicaltrials.gov.
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company's proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in lung cancer,
leukaemia and COVID-19. A first-in-class functional blocking anti-AXL antibody,
tilvestamab, is undergoing phase I clinical testing. In parallel, BerGenBio is
developing a companion diagnostic test to identify patient populations most
likely to benefit from bemcentinib: this is expected to facilitate more
efficient registration trials supporting a precision medicine-based
commercialisation strategy.
BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit www.bergenbio.com
Contacts
Richard Godfrey CEO, BerGenBio ASA
+47 917 86 304
Rune Skeie, CFO, BerGenBio ASA
+47 917 86 513
International Media Relations
Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs
Consilium Strategic Communications
+44 20 3709 5700
Media Relations in Norway
Jan Petter Stiff, Crux [email protected]
+47 995 13 891
Forward looking statements
This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.